UK Regulator Warns of Small Risk of Severe Acute Pancreatitis with Weight-Loss Jabs
A warning has been issued by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) regarding weight-loss medications. According to the regulator, patients taking certain diabetes injections and weight-loss jabs are at a small risk of developing severe acute pancreatitis.
The MHRA received an increase in reports of this condition among patients using semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), prompting the regulator to update its guidance. Since early 2024, approximately 1.6 million adults in England, Wales, and Scotland have used GLP-1 medications to lose weight.
The rare condition occurs when the pancreas becomes suddenly inflamed, causing severe abdominal pain, nausea, and fever. In most cases, patients require hospitalization.
While acknowledging that acute pancreatitis is a rare occurrence, the MHRA has taken action to address concerns raised by an increase in reports through its yellow card scheme, which monitors any adverse reactions to medications and medical devices.
To date, there have been 1,143 reports of acute and chronic pancreatitis among patients taking semaglutide or tirzepatide, with 17 reported fatalities. Nearly all of these cases were logged in 2025, with the majority related to tirzepatide.
Dr. Alison Cave, chief safety officer at the MHRA, emphasized that patient safety is a top priority and that the regulator continually monitors the safety and efficacy of licensed medicines. She noted that while the risk of developing severe side effects is small, it's essential for patients and healthcare professionals to be aware of associated symptoms.
The MHRA recommends that patients taking GLP-1s report any symptoms such as severe stomach pain accompanied by nausea and vomiting to their healthcare professional and via the yellow card scheme. A new study collaboration between the MHRA and Genomics England aims to investigate whether an individual's genes may influence the risk of adverse reactions, with the ultimate goal of predicting which patients are most at risk.
The manufacturers of Wegovy, Ozempic, and Mounjaro have responded by emphasizing patient safety as their top priority. They advise patients to use these medications only for approved indications under the strict supervision of a healthcare professional and encourage them to report any side effects.
A warning has been issued by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) regarding weight-loss medications. According to the regulator, patients taking certain diabetes injections and weight-loss jabs are at a small risk of developing severe acute pancreatitis.
The MHRA received an increase in reports of this condition among patients using semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), prompting the regulator to update its guidance. Since early 2024, approximately 1.6 million adults in England, Wales, and Scotland have used GLP-1 medications to lose weight.
The rare condition occurs when the pancreas becomes suddenly inflamed, causing severe abdominal pain, nausea, and fever. In most cases, patients require hospitalization.
While acknowledging that acute pancreatitis is a rare occurrence, the MHRA has taken action to address concerns raised by an increase in reports through its yellow card scheme, which monitors any adverse reactions to medications and medical devices.
To date, there have been 1,143 reports of acute and chronic pancreatitis among patients taking semaglutide or tirzepatide, with 17 reported fatalities. Nearly all of these cases were logged in 2025, with the majority related to tirzepatide.
Dr. Alison Cave, chief safety officer at the MHRA, emphasized that patient safety is a top priority and that the regulator continually monitors the safety and efficacy of licensed medicines. She noted that while the risk of developing severe side effects is small, it's essential for patients and healthcare professionals to be aware of associated symptoms.
The MHRA recommends that patients taking GLP-1s report any symptoms such as severe stomach pain accompanied by nausea and vomiting to their healthcare professional and via the yellow card scheme. A new study collaboration between the MHRA and Genomics England aims to investigate whether an individual's genes may influence the risk of adverse reactions, with the ultimate goal of predicting which patients are most at risk.
The manufacturers of Wegovy, Ozempic, and Mounjaro have responded by emphasizing patient safety as their top priority. They advise patients to use these medications only for approved indications under the strict supervision of a healthcare professional and encourage them to report any side effects.